Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
Minerva Neurosciences (Nasdaq:NERV), a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
Rhea-AI Summary
Minerva Neurosciences (Nasdaq:NERV), a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, will participate in the 2026 Jefferies Global Healthcare Conference in New York from June 2-4, 2026.
CEO Remy Luthringer will join a fireside chat on June 4 at 4:20 PM ET, with a live webcast and a 90-day replay available.
Positive
- None.
Negative
- None.
Details
News Market Reaction – NERV
In the May 19 session, NERV declined 8.02%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- GAAP net loss
- $125.4M
- Q1 2026 GAAP net loss as reported in 10-Q
- Warrant liability change
- $109.4M
- Non-cash increase in fair value of warrant liability in Q1 2026
- Cash and equivalents
- $78.2M
- Cash, cash equivalents, marketable securities and restricted cash at March 31, 2026
- Shelf registration size
- $200,000,000
- Maximum aggregate offering amount under S-3 shelf filed March 11, 2026
- Phase 3 enrollment
- 380 patients
- Planned enrollment for confirmatory Phase 3 C19 trial of roluperidone
- Trial sites
- 40 sites
- Approximate number of global sites for Phase 3 roluperidone trial
- Net loss per share
- $2.86
- Q1 2026 GAAP net loss per share
- Balyasny ownership
- 9.99%
- Beneficial ownership of Minerva common stock per Schedule 13G/A
Historical Context
-
Q1 2026 results and Phase 3 trial initiation details for roluperidone.
-
Appointment of new Chief Business Officer and General Counsel and executive transition.
-
First patient screened in global confirmatory Phase 3 trial of roluperidone.
-
Open‑label safety data for roluperidone with olanzapine showing no significant adverse effects.
-
Announcement of presentation at The Stifel 2026 Virtual CNS Forum.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in the 2026 Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
| 2026 Jefferies Global Healthcare Conference | |
| Format: | Fireside chat |
| Day/Time: | Thursday, June 4 at 4:20 PM ET |
| Webcast: | Link here |
If you are interested in meeting with the Minerva team during the conference, please reach out to your Jefferies representative.
A replay of the presentation will be available on the Company's Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with improved therapeutic options, including roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:
Frederick Ahlholm
Chief Financial Officer
Minerva Neurosciences, Inc.
FAhlholm@minervaneurosciences.com
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.